D. Oh

Jin‐Young Jang, Y. Bang, Kyubo Kim, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy

D. Noh, H. Ryu, S. Im, 2016, Journal of Cancer Research and Clinical Oncology.

The Prognostic Importance of the Number of Metastatic Lymph Nodes for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiotherapy for Extrahepatic Bile Duct Cancer

Jin‐Young Jang, Y. Bang, S. Im, 2015, Journal of Gastrointestinal Surgery.

The influence of the treatment response on the impact of resection margin status after preoperative chemoradiotherapy in locally advanced rectal cancer

Seung-Yong Jeong, Y. Bang, S. Im, 2013, BMC Cancer.

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer

Seung-Yong Jeong, Y. Bang, S. Im, 2011, Cancer Chemotherapy and Pharmacology.

Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.

Y. Bang, Dong-Wan Kim, D. Heo, 2004, Japanese journal of clinical oncology.

Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis

Junshik Hong, Y. Bang, S. Im, 2011, Cancer Chemotherapy and Pharmacology.

Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021

H. Wang, T. Hibi, Y. Iwashita, 2020, Journal of hepato-biliary-pancreatic sciences.

Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer

Myung Ah Lee, Tae Won Kim, J. Roh, 2011, Investigational New Drugs.

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy

Seung-Yong Jeong, Y. Bang, N. Cho, 2013, British Journal of Cancer.

Effect of Suboptimal Chemotherapy on Preoperative Chemoradiation in Rectal Cancer

Y. Bang, S. Im, G. Kang, 2009 .

A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors

Y. Bang, J. W. Kim, Keun-Wook Lee, 2020, Clinical and translational science.

Adjuvant Chemotherapy in Microsatellite Instability–High Gastric Cancer

Y. Bang, S. Im, Ji‐Won Kim, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival

Y. Bang, S. Im, J. W. Kim, 2013, Gastric Cancer.

Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.

Y. Bang, S. Im, Keun-Wook Lee, 2008, Japanese journal of clinical oncology.

Adjuvant Treatment for Gastric Cancer

Y. Bang, D. Oh, 2019, Surgery for Gastric Cancer.

Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.

Jin‐Young Jang, Y. Bang, S. Im, 2008, Japanese journal of clinical oncology.

Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial

S. Choi, Joon-Oh Park, D. Yoon, 2018, Annals of surgery.

Discrepancies of the Values on the Withholding Futile Interventions between Physician and Family Members of Terminal Cancer Patients.

Y. Bang, D. Heo, D. Y. Kim, 2001, Cancer research and treatment : official journal of Korean Cancer Association.

DNA methyltransferase 3B mutant in ICF syndrome interacts non-covalently with SUMO-1

Y. Bang, Sung-Hak Kim, S. Im, 2008, Journal of Molecular Medicine.

A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer

Y. Bang, S. Im, J. W. Kim, 2015, Cancer Chemotherapy and Pharmacology.

Capecitabine for the treatment of gastric cancer

Y. Bang, D. Oh, Tae-Yong Kim, 2015, Expert review of gastroenterology & hepatology.

Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer

S. Im, Keun-Wook Lee, J. S. Lee, 2009, Acta oncologica.

Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy.

Jin‐Young Jang, Y. Bang, S. Im, 2016, Anticancer research.

Postoperative chemoradiotherapy in high risk locally advanced gastric cancer

Y. Bang, S. Im, Kyubo Kim, 2012, Radiation oncology journal.

Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study.

Y. Bang, Dong-Wan Kim, D. Heo, 2011, Japanese journal of clinical oncology.

The role of PET/CT in detection of gastric cancer recurrence

Y. Bang, Dong-Wan Kim, D. Heo, 2009, BMC Cancer.

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer

S. Kang, G. Cheon, D. Oh, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer

Y. Bang, Dong-Wan Kim, D. Heo, 2013, Cancer research and treatment : official journal of Korean Cancer Association.

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

S. Libutti, James C Yao, N. Fazio, 2017, Neuroendocrinology.

Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: A retrospective study

Y. Bang, S. Im, J. Rhee, 2010, Journal of gastroenterology and hepatology.

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Y. Bang, Dong-Wan Kim, S. Im, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer

Y. Bang, D. Heo, S. Im, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.

Y. Bang, Dong-Wan Kim, D. Heo, 2010, Lung cancer.

Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer.

Y. Bang, Dong-Wan Kim, D. Heo, 2008, Cancer research and treatment : official journal of Korean Cancer Association.

Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer

C. Kang, Y. Bang, Dong-Wan Kim, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

P. Sharma, L. Dirix, B. Keam, 2019, Clinical Cancer Research.

Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology

Jieun Park, Y. Bang, D. Oh, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells.

Y. Bang, S. Im, D. Oh, 2010, International journal of oncology.

Prognostic Factors Affecting the Outcome of Salvage Radiotherapy for Isolated Locoregional Recurrence After Mastectomy

W. Han, D. Noh, Y. Bang, 2010, American journal of clinical oncology.

Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation

Y. Bang, S. Im, D. Oh, 2009, Journal of gastroenterology and hepatology.

Overexpression of A-kinase anchoring protein 12A activates sterol regulatory element binding protein-2 and enhances cholesterol efflux in hepatic cells.

Ju-Hee Lee, Y. Bang, Sung-Hak Kim, 2008, The international journal of biochemistry & cell biology.

A-kinase anchoring protein 12 regulates the completion of cytokinesis.

Y. Bang, Sung-Hak Kim, S. Im, 2008, Biochemical and biophysical research communications.

Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells

Y. Bang, S. Im, D. Oh, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

Young Tae Kim, Doo Hyun Chung, Tae-You Kim, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.

K. Lee, Y. Bang, J. Kim, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer.

Keun-Wook Lee, D. Oh, J. Kim, 2007, Cancer research and treatment : official journal of Korean Cancer Association.

TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials

S. Im, Jung-Hwan Yoon, Y. Kim, 2016, British Journal of Cancer.

Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer

Y. Bang, Keun-Wook Lee, D. Oh, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors

Y. Bang, Dong-Wan Kim, D. Heo, 2014, Journal of Korean medical science.

The Impact of Primary Tumor Resection on the Survival of Patients with Stage IV Breast Cancer

W. Han, D. Noh, Sung-Won Kim, 2010 .

Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors

D. Noh, H. Moon, Dong-Wan Kim, 2013, Journal of breast cancer.

Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer

Hyun Woo Kwon, G. Cheon, Y. Bang, 2017, The Journal of Nuclear Medicine.

Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion

Myung Ah Lee, D. Oh, B. Ryoo, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4

James C Yao, N. Fazio, M. Pavel, 2017, OncoTargets and therapy.

Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas

Y. Bang, D. Oh, S. Shin, 2012, Cancer.

Public awareness of gastric cancer risk factors and disease screening in a high risk region: a population-based study.

Y. Bang, K. Choi, D. Oh, 2009, Cancer research and treatment : official journal of Korean Cancer Association.

Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study

James C Yao, Tetsuhide Ito, M. Izquierdo, 2019, OncoTargets and therapy.

A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers

D. Oh, Ah-Rong Nam, Ju-hee Bang, 2021, Oncogene.

Ataxia‐telangiectasia‐mutated protein expression with microsatellite instability in gastric cancer as prognostic marker

Y. Bang, S. Im, J. W. Kim, 2014, International journal of cancer.

The influence of treatment response on the impact of resection margin status after preoperative chemoradiotherapy in rectal cancer.

Seung-Yong Jeong, Y. Bang, G. Kang, 2013 .

TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy

Y. Bang, S. Im, J. W. Kim, 2020, Cancers.

Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.

Y. Bang, S. Im, J. W. Kim, 2018, Cancer letters.

Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution

Jin‐Young Jang, Y. Bang, Kyubo Kim, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.

Y. Bang, S. Im, D. Oh, 2008, International journal of oncology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition

Y. Bang, J. E. Park, D. Oh, 2017, Molecular Cancer Therapeutics.

Phase II trial of dacomitinib in patients with HER2-positive gastric cancer

Y. Bang, S. Im, J. W. Kim, 2016, Gastric Cancer.

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, B. Solomon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.

Jieun Park, Y. Bang, D. Oh, 2017, Cancer letters.

Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.

Y. Bang, S. Im, Jung-Hwan Yoon, 2010, Anticancer research.

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer

Y. Doki, Keunchil Park, Chih-Hung Hsu, 2022, Cancer medicine.

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.

M. Rebelatto, J. W. Kim, P. Mccoon, 2022, The lancet. Gastroenterology & hepatology.

Prospective evaluation of changes in tumor size and tumor metabolism in advanced gastric cancer undergoing chemotherapy: association and clinical implication

Hyun Woo Kwon, Seunggyun Ha, G. Cheon, 2016, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Optimal timing of influenza vaccination during 3‐week cytotoxic chemotherapy cycles

Yunhee Choi, Dong-Wan Kim, D. Heo, 2017, Cancer.

LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

S. Oh, S. Sym, I. Chung, 2020 .

Treatment for unresectable gastric cancer

Y. Bang, D. Oh, T. Y. Kim, 2015 .

GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer

Y. Bang, J. E. Park, D. Oh, 2019, Gastric Cancer.

Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.

E. Van Cutsem, R. Walgren, Li‐Tzong Chen, 2020 .

FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

E. Van Cutsem, M. Borad, G. Abou-Alfa, 2019, Annals of Oncology.

ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation

A. Zhu, M. Borad, G. Abou-Alfa, 2019, Annals of Oncology.

The impact of perioperative CA19‐9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma

Jin‐Young Jang, Kyubo Kim, D. Oh, 2018, Journal of surgical oncology.

Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial

G. Abou-Alfa, S. Clarke, E. Hitre, 2019, Annals of Oncology.

Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.

G. Abou-Alfa, S. Clarke, E. Hitre, 2019, Journal of Clinical Oncology.

FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.

M. Borad, J. Furuse, H. Chang, 2019, Journal of Clinical Oncology.

Preliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma (CCA).

W. Su, D. Oh, L. Shen, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal Tract, and Lung)

Y. Bang, Dong-Wan Kim, D. Heo, 2012, American journal of clinical oncology.

Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: second interim overall survival (OS) results from the RADIANT-4 Study.

James C Yao, N. Fazio, M. Pavel, 2016 .

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer

Jin‐Young Jang, Y. Bang, S. Im, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

J. W. Kim, M. Ikeda, Li‐Tzong Chen, 2022, NEJM evidence.

Phase II study of low-dose paclitaxel and cisplatin as second-line therapy in 5-fluorouracil and platinum pretreated gastric cancer

D. Heo, S. Im, Keun-Wook Lee, 2005 .

AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results

K. Flaherty, M. Voss, G. Iyer, 2019, Hepatobiliary surgery and nutrition.

Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study.

R. Kelley, A. Nagrial, D. Oh, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.

Y. Bang, Dong-Wan Kim, D. Heo, 2005, Japanese journal of clinical oncology.

A case of primary breast synovial sarcoma diagnosed in a young female patient

Ji Won Kim, S. Im, N. Cho, 2010 .

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Y. Bang, Dong-Wan Kim, S. Im, 2010, BMC Cancer.

Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy.

Eun Sun Lee, Jin‐Young Jang, J. Lee, 2018, AJR. American journal of roentgenology.

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea

W. Han, D. Noh, H. Moon, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis

Y. Bang, S. Im, D. Oh, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer

Y. Bang, Ji‐Won Kim, J. E. Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Chemical Therapeutics Discovery & Preclinical Development Antitumor Activity of Saracatinib ( AZD 0530 ) , a cSrc / Abl Kinase Inhibitor , Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Y. Bang, P. Elvin, S. Im, 2013 .

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Y. Bang, P. Elvin, S. Im, 2012, Molecular Cancer Therapeutics.

Risk stratification and prognostic nomogram for post-recurrence overall survival in patients with recurrent extrahepatic cholangiocarcinoma.

Jin‐Young Jang, Y. Bang, Kyubo Kim, 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Distant metastasis risk stratification for patients undergoing curative resection followed by adjuvant chemoradiation for extrahepatic bile duct cancer.

Jin‐Young Jang, Y. Bang, S. Im, 2012, International journal of radiation oncology, biology, physics.

A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.

Y. Bang, Dong-Wan Kim, D. Heo, 2004, Oncology reports.

Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II study.

R. Guimbaud, D. Oh, J. Szántó, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

J. Desai, K. Flaherty, B. Goh, 2016 .

P. Ascierto, W. Miller, M. Maio, 2022, European journal of cancer.

Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy

Y. Bang, Dong-Wan Kim, D. Heo, 2012, Supportive Care in Cancer.

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer

D. Oh, Ah-Rong Nam, Ju-hee Bang, 2021, Cancer research and treatment.

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors

Joon-Oh Park, Y. Bang, Dae-Ho Lee, 2017, The Oncologist.

High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer patients.

Jin‐Young Jang, Kyubo Kim, D. Oh, 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery.

Kyubo Kim, D. Oh, E. Chie, 2017, The British journal of radiology.

Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution

Jin‐Young Jang, Y. Bang, Kyubo Kim, 2017, Oncotarget.

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review

Joon-Oh Park, Chiun Hsu, Li‐Tzong Chen, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.

Sung Sook Lee, B. Melichar, Yoon-Koo Kang, 2016 .

Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study.

M. Fakih, A. Hansen, H. Chung, 2022, European journal of cancer.

Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer.

W. Han, D. Noh, Y. Bang, 2014, Anticancer research.

A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09

E. Cho, S. Im, K. Jung, 2015, Supportive Care in Cancer.

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer

A. Drilon, J. Berlin, D. Hyman, 2020, Zeitschrift für Gastroenterologie.

Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer

Jin‐Young Jang, Y. Bang, S. Im, 2016, PloS one.

A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

Joon-Oh Park, A. Varghese, D. Melisi, 2019, Journal of Clinical Oncology.

Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.

J. Ajani, F. Meric-Bernstam, A. El-Khoueiry, 2021 .

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial

G. Viale, L. De Cecco, M. Dugo, 2021, Molecular oncology.

Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment.

D. Noh, H. Moon, N. Cho, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.

J. Mayordomo, F. Meric-Bernstam, A. El-Khoueiry, 2022, The Lancet. Oncology.

HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).

S. Bates, J. Lacy, E. Van Cutsem, 2020 .

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Joon-Oh Park, M. Reni, E. Van Cutsem, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer

Y. Bang, J. E. Park, D. Oh, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.

J. Ajani, Y. Bang, Y. Janjigian, 2018 .

Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer

S. Im, T. Kim, D. Oh, 2008 .

A First‐in‐Human Phase I Study of GC1118, a Novel Anti‐Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors

S. Hahn, Y. Bang, J. W. Kim, 2019, The oncologist.

APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

J. Berlin, A. Biankin, P. Philip, 2019, Journal of Clinical Oncology.

The beneficial effect of palliative resection in metastatic colorectal cancer

S. Im, G. Kang, D. Oh, 2013, British Journal of Cancer.

Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy

S. Im, Keun-Wook Lee, Jung-Hwan Yoon, 2014, Breast Cancer.

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Joon-Oh Park, J. Berlin, A. Biankin, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study.

Joon-Oh Park, M. Borad, H. Chang, 2021 .

Artificial nutrition and hydration in terminal cancer patients: the real and the ideal

Y. Bang, D. Heo, S. Im, 2007, Supportive Care in Cancer.

Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies

Y. Bang, D. Oh, D. Seog Heo, 2004, Cancer.

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Joon-Oh Park, M. Reni, E. Van Cutsem, 2019, The New England journal of medicine.

Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy

M. Reni, M. Tempero, H. Riess, 2019, Pancreas.

Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.

D. Noh, Y. Bang, S. Im, 2011, Japanese journal of clinical oncology.

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

James C Yao, N. Fazio, M. Pavel, 2016, The Lancet.

Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.

S. Libutti, James C Yao, N. Fazio, 2016 .

Safety and efficacy of everolimus in advanced nonfunctional Neuroendocrine Tumors (NET) of lung or Gastrointestinal (GI) origin: findings of the randomized, placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study

Y. Shimada, James C Yao, N. Fazio, 2016 .

134ORADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract

Y. Shimada, James C Yao, S. Singh, 2015 .

5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study

Y. Shimada, James C Yao, N. Fazio, 2015 .

Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer

Y. Bang, S. Im, S. K. Baek, 2011, BMC gastroenterology.

Recent Progress in Immunotherapy for Gastric Cancer

D. Oh, Tae-Yong Kim, J. Yoon, 2023, Journal of gastric cancer.

Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients

W. Han, D. Noh, H. Ryu, 2019, British Journal of Cancer.

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

G. Giaccone, P. Moore, R. Lechleider, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

T. Yoshikawa, Yoon-Koo Kang, S. Oh, 2017, The Lancet.

Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib

S. Im, Y. Kim, Jeong‐Hoon Lee, 2020, Clinical Cancer Research.

Therapeutic implication of HER2 in advanced biliary tract cancer

Y. Bang, S. Im, Ji‐Won Kim, 2016, Oncotarget.

Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors

Y. Bang, D. Heo, Se-Hoon Lee, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer

Y. Bang, S. Im, Keun-Wook Lee, 2014, Cancer Chemotherapy and Pharmacology.

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Joon-Oh Park, S. Bates, J. Lacy, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells

Y. Bang, M. O’Connor, S. Im, 2015, Breast Cancer Research.

A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

Y. Bang, Dong-Wan Kim, B. Cho, 2014, BMC Cancer.

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Y. Bang, M. O’Connor, S. Im, 2013, Molecular Cancer Therapeutics.

AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells

Y. Bang, A. Lau, M. O’Connor, 2017, Molecular Cancer Therapeutics.

Anti‐tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells

Y. Bang, A. Lau, M. O’Connor, 2017, International journal of cancer.

The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines

Y. Bang, S. Im, D. Oh, 2012, Investigational New Drugs.

HER2-targeted therapies — a role beyond breast cancer

Y. Bang, D. Oh, Yung-Jue Bang, 2019, Nature Reviews Clinical Oncology.

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment

A. Blackler, C. Ock, S. Thyparambil, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells

Young-Kwang Yoon, Tae-You Kim, Hye-Jin Kim, 2012, Anti-cancer drugs.

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

E. Van Cutsem, M. Borad, G. Abou-Alfa, 2020, The Lancet. Oncology.

ATM in DNA repair in cancer.

D. Oh, M. Jin, 2019, Pharmacology & therapeutics.

NTRK- and RET-fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.

Young Shin Song, B. Ahn, O. Kim, 2021, The Journal of clinical investigation.

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

Myung Ah Lee, P. Philip, A. Hezel, 2019, JAMA oncology.

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

S. Choe, A. Zhu, M. Borad, 2021, JAMA oncology.

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

A. Zhu, M. Borad, G. Abou-Alfa, 2020, The Lancet. Oncology.

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Joon-Oh Park, B. Somer, N. Le, 2014, European journal of cancer.

Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer

J. Ajani, J. Mayordomo, F. Meric-Bernstam, 2019 .

Prognostic effects of abnormal DNA damage response protein expression in breast cancer

W. Han, D. Noh, H. Ryu, 2019, Breast Cancer Research and Treatment.

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

L. Pusztai, A. Lluch, V. Semiglazov, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Antibodies that Inhibit Specific Cellular Pathways in Gastric Cancer

Y. Bang, D. Oh, 2017 .

Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications

Y. Bang, S. Im, C. Ock, 2016, Gastric Cancer.

Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer

Y. Bang, S. Im, C. Ock, 2015, Gastric Cancer.

Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study

Joon-Oh Park, M. Borad, D. O'Brien, 2022, Hepatology.

Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers

Y. Bang, S. Im, D. Oh, 2012, Laboratory Investigation.

Prognostic implication of antitumor immunity measured by the neutrophil–lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer

Y. Bang, S. Im, C. Ock, 2017, Gastric Cancer.

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Tae-You Kim, Sung-Hak Kim, Y. Bang, 2008, Molecular Cancer Therapeutics.

OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.

Y. Bang, S. Im, D. Oh, 2013, Cancer letters.

17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.

W. Han, D. Noh, Kap-Seok Yang, 2011, Experimental and Therapeutic Medicine.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.

Y. Bang, Dong-Wan Kim, D. Heo, 2009, Lung cancer.

Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment.

Y. Bang, Dong-Wan Kim, D. Heo, 2008, Lung cancer.

Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review

Yoon-Koo Kang, W. Yeo, K. Yeh, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer

S. Im, Y. Jeon, I. Park, 2013, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

A. Drilon, Keunchil Park, S. Leyvraz, 2022, European journal of endocrinology.

MicroRNA-17 Acts as a Tumor Chemosensitizer by Targeting JAB1/CSN5 in Triple-Negative Breast Cancer.

A. Sahin, F. Claret, M. Edgerton, 2019, Cancer letters.

A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma

S. Im, D. Oh, Tae-You Kim, 2018, BMC Cancer.

Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer

Y. Bang, Dong-Wan Kim, D. Heo, 2007, Pharmacogenetics and genomics.

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.

Jin Won Kim, Young-Kwang Yoon, Tae-You Kim, 2008, Cancer letters.

Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer

Tae-Yong Kim, Jin Won Kim, Woo Ho Kim, 2015, Clinical Cancer Research.

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy

Jieun Park, Y. Bang, S. Im, 2016, Oncotarget.

Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ Hybridization

Y. Bang, S. Im, J. W. Kim, 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6

Y. Bang, S. Im, Keun-Wook Lee, 2010, Cancer science.

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

Young Suk Park, Joong Bae Ahn, Jae Ho Byun, 2009, Cancer Chemotherapy and Pharmacology.

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab

T. Yoshikawa, Yoon-Koo Kang, S. Oh, 2021, Gastric Cancer.

Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.

Joon-Oh Park, M. Reni, G. Tortora, 2021 .

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

P. Philip, D. Porter, E. Van Cutsem, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

More Accurate Prediction of Metastatic Pancreatic Cancer Patients’ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity

Y. Bang, S. Im, D. Oh, 2016, PloS one.

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

Yoon-Koo Kang, S. Oh, Li‐Tzong Chen, 2022, The Lancet. Oncology.

Prognostic Value of Splenic Artery Invasion in Patients Undergoing Adjuvant Chemoradiotherapy after Distal Pancreatectomy for Pancreatic Adenocarcinoma

Jin‐Young Jang, Y. Bang, S. Im, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer

Seung-Yong Jeong, Y. Bang, S. Im, 2013, Cancer Chemotherapy and Pharmacology.

Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.

W. Han, D. Noh, Y. Bang, 2011, Tumori.

Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma

Y. Bang, S. Im, Ja-june Jang, 2015, BMC Cancer.

Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy

D. Noh, W. Moon, H. Moon, 2012, Breast Cancer Research and Treatment.

KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX

Seung-Yong Jeong, Y. Bang, N. Cho, 2014, Annals of Surgical Oncology.

Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer

Y. Bang, Keun-Wook Lee, D. Oh, 2013, Investigational New Drugs.

VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib

Y. Bang, Dong-Wan Kim, D. Heo, 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy

W. Han, D. Noh, Y. Bang, 2012, Oncology.

Phase II Trial of Vinorelbine and Cisplatin Chemotherapy in Advanced Non-Small Cell Lung Cancer.

Y. Bang, J. Kim, D. Heo, 2001, Cancer research and treatment : official journal of Korean Cancer Association.

Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.

Young-Kwang Yoon, Tae-You Kim, Hyun-Jin Nam, 2011, Cancer letters.

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

Young-Kwang Yoon, Tae-You Kim, Y. Bang, 2010, Molecular carcinogenesis.

Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.

Y. Bang, Sang-Il Kim, Dong-Wan Kim, 2005, Japanese journal of clinical oncology.

Efficacy of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer.

D. H. Lee, Y. Bang, J. Kim, 2001, Cancer research and treatment : official journal of Korean Cancer Association.

A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions

W. Han, D. Noh, Y. Bang, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer

W. Han, D. Noh, Sung-Won Kim, 2009, Annals of Surgical Oncology.

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

W. Han, D. Noh, Y. Bang, 2008, BMC Cancer.

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

W. Han, D. Noh, Y. Bang, 2007, BMC Cancer.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

W. Han, D. Noh, Y. Bang, 2007, BMC cancer.

Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy

Jin‐Young Jang, W. Kwon, J. Kang, 2021, Journal of hepato-biliary-pancreatic sciences.

A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations

M. Galsky, S. Piha-Paul, S. Pal, 2021, Investigational New Drugs.

Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy

S. Kang, G. Cheon, D. Oh, 2021, Scientific Reports.

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

Dong Sook Kim, S. Park, Keun-Wook Lee, 2021, Therapeutic advances in medical oncology.

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.

S. Roychowdhury, A. Lamarca, I. Borbath, 2020, Future oncology.

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies

Hong Wang, H. Rugo, A. Italiano, 2020, International journal of cancer.

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

M. Kudo, M. Osada, M. Ikeda, 2020, Journal for immunotherapy of cancer.

Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study

S. Kang, G. Cheon, Y. Bang, 2019, The Journal of Nuclear Medicine.

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

T. Yoshikawa, Yoon-Koo Kang, S. Oh, 2019, Gastric Cancer.

The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy

Y. Bang, J. E. Park, D. Oh, 2019, Cancer medicine.

Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis

Y. Bang, S. Yoon, Dong-Wan Kim, 2019, ESMO Open.

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia

Kazuhiro Yoshida, T. Yoshikawa, Yoon-Koo Kang, 2019, JAMA Network Open.

Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer

Y. Bang, D. Oh, Ah-Rong Nam, 2019, Scientific Reports.

Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer

Jin‐Young Jang, Youngmin Han, W. Kwon, 2019, Journal of hepato-biliary-pancreatic sciences.

Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX

Jin‐Young Jang, Youngmin Han, W. Kwon, 2020, Gut and liver.

Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study

Joon-Oh Park, Y. Bang, K. Rau, 2019, Cancer science.

Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group

Joo Hoon Kim, Guk Jin Lee, Joon-Oh Park, 2019, Therapeutic advances in medical oncology.

A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo

J. Furuse, Chung-Pin Li, M. Ikeda, 2017, Cancer Chemotherapy and Pharmacology.

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations

Y. Bang, S. Im, E. Park, 2011, International journal of oncology.

Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.

Joon-Oh Park, M. Monga, L. Shen, 2019, Journal of Clinical Oncology.

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)

Sung-Bae Kim, J. Ahn, Yeon-Hee Park, 2022, Cancer research and treatment.

Does adjuvant radiotherapy suppress liver regeneration after partial hepatectomy?

Jin‐Young Jang, Y. Bang, S. Im, 2009, International journal of radiation oncology, biology, physics.

ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy

W. Han, D. Noh, S. Im, 2014, Cancer science.

A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.

Y. Bang, Y. Kim, J. Kim, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer

Y. Bang, S. Im, Keun-Wook Lee, 2010, Journal of Korean medical science.

Chemical Therapeutics RAD 51 CDe fi cient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Y. Bang, M. O’Connor, S. Im, 2013 .

Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy

D. Noh, Y. Bang, Dong-Wan Kim, 2011, Journal of Cancer Research and Clinical Oncology.

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis

W. Han, D. Noh, Y. Bang, 2011, Breast Cancer Research.

Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation

Tae Won Kim, H. Chang, Yoon-Koo Kang, 2013, Cancer Chemotherapy and Pharmacology.

Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer

W. Han, D. Noh, H. Ryu, 2016, Breast Cancer Research and Treatment.

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.

M. Borad, G. Abou-Alfa, D. Melisi, 2021 .

A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3).

M. Borad, J. Furuse, J. Bridgewater, 2020 .

Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity.

W. Han, D. Noh, Y. Bang, 2010, Japanese journal of clinical oncology.

Metaplastic Breast Carcinoma: Clinicopathologic Features and Prognostic Value of Triple Negativity

Tae-You Kim, S. Im, I. Park, 2009 .

Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer

Y. Bang, Dong-Wan Kim, D. Heo, 2007, Journal of Korean medical science.

Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.

Y. Bang, Dong-Wan Kim, D. Heo, 2005, Japanese journal of clinical oncology.

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy

W. Han, D. Noh, K. Kang, 2011, BMC Cancer.

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.

Y. Bang, H. Min, Dong-Wan Kim, 2007, Lung cancer.

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

Y. Bang, S. Im, D. Oh, 2009, British Journal of Cancer.

Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma

Jin‐Young Jang, Y. Bang, S. Im, 2012, Clinical and Translational Oncology.

DNA methyltransferase 3B acts as a co-repressor of the human polycomb protein hPc2 to repress fibroblast growth factor receptor 3 transcription.

Ju-Hee Lee, Y. Bang, Sung-Hak Kim, 2008, The international journal of biochemistry & cell biology.

Zinc-fingers and homeoboxes 1 (ZHX1) binds DNA methyltransferase (DNMT) 3B to enhance DNMT3B-mediated transcriptional repression.

Ju-Hee Lee, Y. Bang, Sung-Hak Kim, 2007, Biochemical and biophysical research communications.

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach.

A. Drilon, J. Berlin, B. Geoerger, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker

Y. Bang, Dong-Wan Kim, D. Heo, 2008, BMC Cancer.

Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX

Tae-Yong Kim, Kyu Joo Park, Seung-Yong Jeong, 2015, Clinical Epigenetics.

Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer

Y. Bang, S. Im, W. Kim, 2012, Investigational New Drugs.

A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors

Yeon-Hee Park, B. Keam, Jeeyun Lee, 2021, Investigational New Drugs.

A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.

P. Philip, A. Zhu, M. Borad, 2016 .

Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy

W. Han, D. Noh, Y. Bang, 2010, Cancer.

Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer

Y. Bang, J. E. Park, D. Oh, 2019, Cancer research and treatment : official journal of Korean Cancer Association.

Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study

T. Yoshikawa, Yoon-Koo Kang, S. Oh, 2021, Gastric Cancer.

Role of adjuvant chemoradiotherapy for ampulla of Vater cancer.

Jin‐Young Jang, Y. Bang, S. Im, 2009, International journal of radiation oncology, biology, physics.

Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.

Jin‐Young Jang, W. Kwon, Kyung Yol Lee, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer

Y. Bang, S. Im, D. Oh, 2016, Oncotarget.

Prognostic Value of p53 and bcl-2 Expression in Patients Treated with Breast Conservative Therapy

W. Han, D. Noh, Y. Bang, 2007, Journal of Korean medical science.

Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing

Seung-Yong Jeong, Y. Bang, Jeong-Sun Seo, 2013, PloS one.

A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.

M. Ducreux, J. Harding, H. Wasan, 2021 .

Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study

Y. Bang, J. W. Kim, D. Oh, 2019, British Journal of Cancer.

Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor.

Dong-Wan Kim, S. Im, B. Keam, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment

W. Han, D. Noh, Y. Bang, 2011, Journal of Neuro-Oncology.

High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.

Jin‐Young Jang, Y. Bang, Sun-Whe Kim, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma

M. Reni, M. Tempero, H. Riess, 2021, Annals of Surgical Oncology.

Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody

K. Kang, Y. Bang, E. Yi, 2012, PloS one.

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer

Y. Bang, S. Im, Weidong Huang, 2012, PloS one.

Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.

Sung-Bae Kim, J. Ahn, Yeon-Hee Park, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy

Y. Bang, S. Im, D. Oh, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives

Y. Bang, Dong-Wan Kim, D. Heo, 2008, British Journal of Cancer.

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Y. Bang, S. Im, D. Oh, 2009, Molecular Cancer Therapeutics.

CPR or DNR? End-of-life decision in Korean cancer patients: a single center’s experience

Y. Bang, Dong-Wan Kim, D. Heo, 2006, Supportive Care in Cancer.

Discrepancies in performance status scores as determined by cancer patients and oncologists: are they influenced by depression?

Y. Shin, H. Jeon, D. Heo, 2007, General hospital psychiatry.

Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy

Y. Bang, S. Y. Park, S. Im, 2009, Journal of Korean medical science.

Magnitude of HER2 amplification as a predictive factor for HER2-overexpressing metastatic breast cancer treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy

J. Kim, S. Im, D. Oh, 2008 .

Is There Any Role of Adjuvant Chemotherapy for T3N0M0 or T1N2M0 Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System?

Y. Bang, S. Im, W. Kim, 2016, Annals of Surgical Oncology.

High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer

Y. Bang, Y. Im, S. Im, 2010, Breast Cancer Research and Treatment.

Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

W. Han, D. Noh, H. Ryu, 2016, BMC Cancer.

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.

E. Van Cutsem, Jiangang Liu, R. Walgren, 2021, The Lancet. Oncology.

Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer

D. Noh, W. Moon, H. Moon, 2013, Annals of Surgical Oncology.

CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy

Y. Bang, S. Im, J. Rhee, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index

Y. Bang, S. Im, D. Oh, 2015, PloS one.

Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy

Y. Bang, S. Im, D. Oh, 2017, Oncotarget.

Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer

Seung-Yong Jeong, Y. Bang, N. Cho, 2016, British Journal of Cancer.

Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer

Seung-Yong Jeong, Y. Bang, N. Cho, 2013, International journal of cancer.

Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.

Y. Bang, W. Kim, Se-Hoon Lee, 2013, Journal of vascular and interventional radiology : JVIR.

Role of Adjuvant Chemoradiotherapy for Duodenal Cancer: An Updated Analysis of Long-Term Follow-Up from Single Institution

Jin‐Young Jang, Kyubo Kim, D. Oh, 2018, World Journal of Surgery.

The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy.

Y. Bang, S. Im, D. Oh, 2013, Journal of pain and symptom management.

Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer

Y. Bang, S. Im, C. Ock, 2016, Gastric Cancer.

RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase.

Ju-Hee Lee, Y. Bang, S. Im, 2010, Cancer letters.

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study

Y. Bang, Dong-Wan Kim, D. Heo, 2008, BMC Cancer.

Myocardial Metastasis in Patient with Cholangiocarcinoma

Hyung‐Kwan Kim, D. Sohn, D. Oh, 2009, Echocardiography.

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

R. Plummer, B. Melichar, Yoon-Koo Kang, 2019, Journal of Immunotherapy for Cancer.

Role of Adjuvant Chemoradiotherapy for Duodenal Cancer: A Single Center Experience

Jin‐Young Jang, Y. Bang, S. Im, 2012, American journal of clinical oncology.

Antibiotic use during the last days of life in cancer patients.

Y. Bang, J. Kim, Dong-Wan Kim, 2006, European journal of cancer care.

Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment

S. Im, D. Park, Keun-Wook Lee, 2023, Cancer medicine.

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer

Y. Bang, Dong-Wan Kim, D. Heo, 2005, Journal of Korean medical science.

Efficacy of reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer (CRC)

Jae Hyun Kim, D. Heo, D. Oh, 2005 .

WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers

D. Oh, Ah-Rong Nam, M. Jin, 2021, Gastric Cancer.

Biliary tract cancer

A. Zhu, J. Valle, B. Nervi, 2021, The Lancet.

Postoperative chemoradiotherapy for gallbladder cancer

Y. Bang, D. Oh, Tae-You Kim, 2012, Strahlentherapie und Onkologie.

Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study

Jin‐Young Jang, Y. Bang, S. Im, 2009, BMC Cancer.

Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.

Y. Janjigian, Keun-Wook Lee, Y. Chao, 2022, Journal of Clinical Oncology.

Avelumab (MSB0010718C), an anti-PD-L1 antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib JAVELIN Solid Tumor trial.

H. Safran, A. Heydebreck, A. Lockhart, 2016 .

Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data

D. Noh, Y. Bang, Dong-Wan Kim, 2012, Journal of breast cancer.

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.

Y. Bang, Dong-Wan Kim, D. Heo, 2006, Lung cancer.

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy

D. Noh, Y. Bang, W. Moon, 2009, Breast Cancer Research and Treatment.

Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer

Y. Bang, S. Im, J. W. Kim, 2013, Cancer Chemotherapy and Pharmacology.

Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less

D. Noh, Sung-Won Kim, Y. Bang, 2010, BMC Cancer.

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer

S. Park, Yoon-Koo Kang, Yeul-Hong Kim, 2017, Cancer Chemotherapy and Pharmacology.

The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer.

Hyunna Lee, S. Im, D. Oh, 2010 .

Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)

Dong Sook Kim, S. Park, Keun-Wook Lee, 2022, Gastric Cancer.

A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer

Y. Bang, S. Oh, Yeul-Hong Kim, 2010, Cancer Chemotherapy and Pharmacology.

Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting

Y. Bang, S. Im, K. Lim, 2011, Cancer Chemotherapy and Pharmacology.

J. Baselga, S. Verma, D. Miles, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.

Joon-Oh Park, P. Sharma, J. Allison, 2018 .

A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.

Myung Ah Lee, P. Philip, A. Hezel, 2018 .

Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).

M. Ikeda, D. Oh, B. Lindmark, 2020 .

Abstract CT111: Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial

R. Plummer, B. Melichar, Yoon-Koo Kang, 2018, Clinical Trials.

First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors.

Toshio Shimizu, F. Meric-Bernstam, M. Rebelatto, 2022, Journal of Clinical Oncology.

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform

J. Ajani, J. Lacy, C. Lopez, 2023, The oncologist.

A Phase II study of 5-fluorouracil and cisplatin systemic chemotherapy for inoperable hepatocellular carcinoma with α fetoprotein as a predictive and prognostic marker.

Y. Bang, Dong-Wan Kim, D. Heo, 2008, Molecular medicine reports.

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2

Young-Kwang Yoon, Tae-You Kim, Ju-Hee Lee, 2009, PloS one.

Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies.

L. Carey, A. Lluch, L. Gianni, 2018, Annals of Oncology.

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells

Y. Bang, M. O’Connor, S. Im, 2015, Breast Cancer Research.

Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution

Jin‐Young Jang, Y. Bang, Kyubo Kim, 2017, Oncotarget.

Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).

Y. Doki, Keunchil Park, M. Ikeda, 2019, Journal of Clinical Oncology.

Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study

J. Mayordomo, F. Meric-Bernstam, M. Beeram, 2022, Cancer Research.

Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication

Hyun Woo Kwon, Seunggyun Ha, G. Cheon, 2017, The Journal of Nuclear Medicine.

Which is better in patients with curatively resected extrahepatic biliary tract cancer? Adjuvant concurrent chemoradiation (CCRT) alone versus CCRT followed by maintenance chemotherapy

Y. Bang, S. Im, K. Lim, 2008 .

Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients

D. Oh, Ah-Rong Nam, M. Jin, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients.

Y. Bang, J. E. Park, D. Oh, 2019, Journal of Clinical Oncology.

Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.

Yoon-Koo Kang, H. Safran, J. Infante, 2016 .

Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma

B. Mellado, Y. Zakharia, M. Teo, 2023, Cancers.

The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.

Y. Bang, Dong-Wan Kim, D. Heo, 2012, Japanese journal of clinical oncology.

Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer.

Kyubo Kim, D. Oh, Eunji Kim, 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Adjuvant Chemoradiotherapy After Curative Resection for Extrahepatic Bile Duct Cancer: A Long-term Single Center Experience

Jin‐Young Jang, Y. Bang, S. Im, 2012, American journal of clinical oncology.

Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer?

Jin‐Young Jang, Y. Bang, S. Im, 2010, International journal of radiation oncology, biology, physics.

Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study

Y. Bang, S. Im, Dong-Yeop Shin, 2011, Cancer Chemotherapy and Pharmacology.

Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

J. Tabernero, R. Xu, H. Arkenau, 2023, Journal of Clinical Oncology.

Pertuzumab in gastrointestinal cancer

Y. Bang, D. Oh, 2016, Expert opinion on biological therapy.

MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.

J. Lacy, T. Bekaii-Saab, O. Rahma, 2018 .

Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.

Suzanne F. Jones, G. Giaccone, Y. Bang, 2015 .

Results of breast‐conserving therapy for multifocal or multicentric breast cancers

W. Han, D. Noh, Y. Bang, 2009 .

Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.

A. Zhu, M. Borad, G. Abou-Alfa, 2021 .

POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).

Joon-Oh Park, L. Schwartz, M. Reni, 2020, Journal of Clinical Oncology.

Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)

Yoon-Koo Kang, H. Song, I. Hwang, 2018, Gastric Cancer.

79TiP A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer

M. Borad, J. Furuse, C. Yoo, 2020 .

Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).

M. Rebelatto, J. W. Kim, D. Oh, 2020 .

A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1

A. Vogel, J. Valle, N. Rokutanda, 2019, Annals of Oncology.

Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors

Y. Bang, Keun-Wook Lee, I. Jang, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer

Y. Bang, D. Oh, Ah-Rong Nam, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma

W. Han, D. Noh, H. Moon, 2011, Breast Cancer Research and Treatment.

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.

M. Ducreux, H. Chang, E. Chen, 2023, The Lancet. Oncology.

Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy

Y. Bang, S. Im, D. Oh, 2016, Nutrition and cancer.

Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients

J. Park, Seung-Yong Jeong, Y. Bang, 2015, BMC Cancer.

Abstract 3496: GC1118, a novel anti-EGFR andtibody, shows more potent antitumor activity regardless of KRAS mutation or high-affinity lignad stimulation compared with cetuximab in gastric cancer

Jieun Park, Y. Bang, D. Oh, 2018, Molecular and Cellular Biology / Genetics.

Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations.

G. Abou-Alfa, D. Oh, A. Hollebecque, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer

Jin‐Young Jang, Y. Bang, S. Im, 2016, American journal of clinical oncology.

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).

J. Ajani, J. Lacy, Y. Bang, 2020, Journal of Clinical Oncology.

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).

J. Ajani, J. Lacy, Y. Bang, 2020, Journal of Clinical Oncology.

MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.

J. Desai, N. Segal, M. Fakih, 2019, Journal of Clinical Oncology.

Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)

M. Ikeda, W. Yong, D. Oh, 2021, ESMO open.

Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.

K. Flaherty, I. Mellinghoff, G. Iyer, 2020 .

Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.

Joon-Oh Park, M. Reni, G. Tortora, 2020 .

Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications.

Y. Bang, S. Im, D. Oh, 2015, The oncologist.

1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer

A. Drilon, S. Leyvraz, D. Hong, 2020 .

Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate

Y. Bang, Dong-Wan Kim, D. Heo, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement.

G. Abou-Alfa, S. Roychowdhury, A. Lamarca, 2022, Journal of Clinical Oncology.

Comparisons of Clinical Outcomes between Weekday-Only and Full-Time, 24-Hour/7-Day Coverage Hospitalist Systems

D. Oh, S. Han, H. Jung, 2020, Journal of Korean medical science.

POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).

M. Reni, G. Tortora, D. Hochhauser, 2016 .

A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Joon-Oh Park, B. Somer, N. Le, 2013 .

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, Y. Bang, 2019 .

A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma

S. Im, D. Oh, Tae-You Kim, 2018, BMC Cancer.

The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen.

Y. Bang, S. Im, J. W. Kim, 2012, Anticancer research.

Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy

S. Im, Y. Jeon, I. Park, 2013, Cancer Chemotherapy and Pharmacology.

Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

J. Mayordomo, Yoon-Koo Kang, M. Beeram, 2019, Annals of Oncology.

Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study

Chia‐Chi Lin, T. Guren, M. Shah, 2023, Cancer.

Nomogram prediction of survival and recurrence in patients with extrahepatic bile duct cancer undergoing curative resection followed by adjuvant chemoradiation therapy.

Jin‐Young Jang, Y. Bang, S. Im, 2013, International journal of radiation oncology, biology, physics.

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.

F. Meric-Bernstam, B. Melichar, K. Jung, 2023, Journal of Clinical Oncology.

AB052. P-20. Phase 2, open-label study of second-line M7824 treatment in patients with locally advanced or metastatic biliary tract cancer

Joon-Oh Park, M. Borad, J. Furuse, 2019, HepatoBiliary Surgery and Nutrition.

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial.

M. Osada, M. Ikeda, D. Oh, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX

Seung-Yong Jeong, Y. Bang, N. Cho, 2015, Clinical Epigenetics.

Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients

W. Han, D. Noh, H. Ryu, 2019, Breast Cancer Research and Treatment.

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers

Y. Vugmeyster, M. Borad, J. Furuse, 2023, Hepatology.

P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer

Joon-Oh Park, M. Borad, J. Furuse, 2021, Annals of Oncology.

Comparison of concurrent chemoradiotherapy and chemotherapy alone for locally advanced pancreatic cancer.

Y. Bang, S. Im, Kyubo Kim, 2014 .

M. Reni, E. Van Cutsem, G. Tortora, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer.

Y. Bang, S. Im, C. Ock, 2015, American journal of cancer research.

Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study

J. Han, Se Hyung Kim, S. Im, 2016, European Radiology.

CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.

Jin‐Young Jang, Y. Bang, H. Min, 2013, World journal of gastroenterology.

A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer

J. Kim, D. Oh, H. Ryoo, 2008 .

Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.

Y. Bang, Dong-Wan Kim, D. Heo, 2006, Japanese journal of clinical oncology.

Perceived needs for the information communication technology (ICT)‐based personalized health management program, and its association with information provision, health‐related quality of life (HRQOL), and decisional conflict in cancer patients

Ju Han Kim, W. Han, D. Noh, 2017, Psycho-oncology.

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX

Y. Bang, Se Hyung Kim, S. Im, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Increased fear of progression in cancer patients with recurrence.

Y. Shin, B. Hahm, E. Shim, 2010, General hospital psychiatry.

Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.

Joon-Oh Park, M. Reni, G. Tortora, 2019, Journal of Clinical Oncology.

Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial.

M. Reni, E. Van Cutsem, G. Tortora, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phosphorylated Akt Expression as a Favorable Prognostic Factor for Patients Undergoing Curative Resection and Adjuvant Chemoradiotherapy for Proximal Extrahepatic Bile Duct Cancer

Jin‐Young Jang, Y. Bang, H. Min, 2017, American journal of clinical oncology.

Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.

Joon-Oh Park, M. Borad, R. Kelley, 2023, Journal of Clinical Oncology.

ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.

D. Oh, Ah-Rong Nam, M. Jin, 2021, Cancer letters.

1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial

M. Reni, G. Tortora, D. Hochhauser, 2020 .

Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer

Y. Bang, S. Im, K. Lim, 2012, Oncology.

Evaluation of the willingness‐to‐pay for cancer treatment in Korean metastatic breast cancer patients: A multicenter, cross‐sectional study

Sung-Bae Kim, H. Chung, D. Oh, 2012, Asia-Pacific journal of clinical oncology.

A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research

Y. Bang, H. Song, H. Kang, 2009, Investigational New Drugs.

The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.

Y. Bang, Dong-Wan Kim, D. Heo, 2010, Lung cancer.

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

Y. Bang, S. Im, D. Oh, 2010, Molecular carcinogenesis.

Src as a Therapeutic Target in Biliary Tract Cancer

Y. Bang, S. Im, Ji‐Won Kim, 2016, Molecular Cancer Therapeutics.

Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6

Y. Bang, S. Im, Keun-Wook Lee, 2010, Cancer science.

W. Han, D. Noh, Y. Bang, 2007, BMC Cancer.

OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.

Y. Bang, S. Im, D. Oh, 2013, Cancer letters.

Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy?

Jin‐Young Jang, Y. Bang, S. Im, 2016, Clinical and Translational Oncology.

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

W. Han, D. Noh, Y. Bang, 2008, BMC Cancer.

Does adjuvant radiotherapy suppress liver regeneration after partial hepatectomy?

Jin‐Young Jang, Y. Bang, S. Im, 2009, International journal of radiation oncology, biology, physics.

POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)

M. Reni, G. Tortora, D. Hochhauser, 2019, Annals of Oncology.

Abstract CT096: Phase 1 study of RO7119929 (TLR7 agonist prodrug) in patients (pts) with advanced primary or metastatic liver cancers

B. Sangro, T. Yau, Chia‐Chi Lin, 2023, Cancer Research.

Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer

Y. Bang, S. Im, J. W. Kim, 2015, Clinical Cancer Research.

Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer.

Keun-Wook Lee, D. Oh, J. Kim, 2007, Cancer research and treatment : official journal of Korean Cancer Association.

Combination of chemotherapy and focused ultrasound for the treatment of unresectable pancreatic cancer: a proof-of-concept study

D. H. Lee, D. Oh, Kyung-Hun Lee, 2022, European Radiology.

Capecitabine for the treatment of gastric cancer

Y. Bang, D. Oh, Tae-Yong Kim, 2015, Expert review of gastroenterology & hepatology.

Abstract A167: A phase I study of MET TKI SAR125844 in Asian patients (pts) with advanced solid tumors

Y. Bang, Tae Won Kim, D. Oh, 2015 .

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Y. Bang, P. Elvin, S. Im, 2012, Molecular Cancer Therapeutics.

A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen.

Y. Bang, Keun-Wook Lee, S. Rha, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).

J. Ajani, G. Ku, Yoon-Koo Kang, 2023, Journal of Clinical Oncology.

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.

Y. Bang, S. Im, J. W. Kim, 2008, Cancer letters.

Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.

Y. Bang, S. Im, J. W. Kim, 2018, Cancer letters.

Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.

F. Meric-Bernstam, A. El-Khoueiry, Yoon-Koo Kang, 2021 .

Antitumor activity of NVP‐AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins

Ju-Hee Lee, Y. Bang, S. Im, 2011, Cancer science.

Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study.

K. Rau, S. Oh, P. Potemski, 2023, Journal of Clinical Oncology.

Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).

J. W. Kim, Li‐Tzong Chen, A. Vogel, 2022, Journal of Clinical Oncology.

A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

Y. Bang, Dong-Wan Kim, B. Cho, 2014, BMC Cancer.

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Y. Bang, Dong-Wan Kim, S. Im, 2010, BMC Cancer.